PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): A network meta-analysis
Số trang: 9
Loại file: pdf
Dung lượng: 1.38 MB
Lượt xem: 13
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
The combinations of PD-1 inhibitors with paclitaxel/cisplatinum (PD-1+TP) and fluoropyrimidine/ cisplatinum (PD-1+FP) both have been shown to improve overall survival (OS) and progression-free survival (PFS) in patients with previously untreated, advanced esophageal squamous cell carcinoma (ESCC).
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Esophageal squamous carcinoma PD-1 inhibitor Meta-analysis Overall survival Immune checkpoint inhibitorsGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 118 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0